MTS105 / METiS Pharmaceuticals - LARVOL DELTA

Preclinical development of an mRNA-encoded T cell engager targeting Glypican-3 with tissue- and tumor-specific enrichment in hepatocellular carcinoma (AACR 2025) - "The mRNA was encapsulated in a novel lipid nanoparticle (LNP) for efficient liver-tropic delivery, forming the complex named MTS105... The mRNA-encoded TCE demonstrated optimal tissue/tumor-specific PK, safety and potent anti-tumor activity in preclinical models. These preclinical studies enabled a first-in-human study to assess its safety and preliminary efficacy which is currently ongoing."

Preclinical • Hematological Malignancies • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • GPC3